Skip to main content

Vasculitis

RheumNow Podcast square

Methotrexate Monitoring (5.13.2022)

May 13, 2022

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Bad news for digitial ulcers in Systemic sclerosis, Readmissions in Lupus and Thrombocytopenia in APL patients.




  1. Risk factors for readmission among 132,400 #SLE hospitalizatiions included

Read Article
Patient,instruction

Making You the Expert of You! (Smart Rules for Patients)

May 10, 2022

You’ve scheduled an appointment with your medical provider - how do you make the most of it? We've gathered these tips and suggestions to share with patients.

Read Article
RheumNow Podcast square

RheumNow Podcast – What You Do For & What You Do To the Patient (4.8.2022)

Apr 08, 2022

Dr. Jack Cush reviews the news and journal articles from the past week and discusses the use of fibroscan in RA, steroid hip injections in OA and famous quotes from a famous cardiologist.




  1. CorEvitas Registry study of173 Axial #PsA pts showed 6 mos of bDMARD/tsDMARD resulted

Read Article
#ClinicalPearl Overall #azathioprine wins for maintenance of remission in ANCA associated #vasculitis with equal remission in MPO+ but less with AZA inPR3+. So use AZA but if not tolerated sometimes MMF is ok. Otherwise consider #Leflunomide or if bad organ involvement #Rituximab https://t.co/efi8cKQ36B
Apr 05, 2022
ALEVIATE - small study of Alemtuzumab (anti-CD52) in 23 refractory ANCA-Assoc vasculitis or Behcets— 16/23 (70%) had either complete (6/23, 26%) or partial (10/23, 44%) response at 6 months. 10 SAE in 7 (30%) pts https://t.co/EciG0Mkn4i https://t.co/7UmDA4NxqV
Dr. John Cush @RheumNow( View Tweet )
Apr 05, 2022
GCA temporal artery

Efficacy and Safety of Mavrilimumab in Giant Cell Arteritis

Mar 14, 2022

A phase II trial in patients with active giant cell arteritis shows that mavrilimumab, a monoclonal antibody against granulocyte-macrophage colony-stimulating factor [GM-CSF]) is capable of inducing clinical remission.

Read Article
ICYMI: Kawasaki Disease Guideline from ACR and Vasculitis Foundationhttps://t.co/ixKL6juqkM https://t.co/Nw4yi0OZPy
Dr. John Cush @RheumNow( View Tweet )
Mar 13, 2022
Kawasaki.jpg

Kawasaki Disease Guideline from ACR and Vasculitis Foundation

ACR
Mar 09, 2022

The American College of Rheumatology (ACR), in partnership with the Vasculitis Foundation (VF), released a new guideline for the management of Kawasaki disease that addresses diagnostic issues relating to Kawasaki disease, the treatment of high-risk patients, and the management of

Read Article
New Download Available! Autoimmune Disease in the USAhttps://t.co/KvsgBUY7mL https://t.co/PSTF7ma6G6
Dr. John Cush @RheumNow( View Tweet )
Mar 07, 2022
ICYMI: FDA approved 2/28/22 IV (intravenous) Actemra for GCA: dose 6mg/kg q4 weeks (don't exceed 600 mg/dose)https://t.co/QhIq6dHGSf

TheDaoIndex @KDAO2011( View Tweet )

Mar 05, 2022
Listen in… Fellow Case Presentations From RWCS 2022 https://t.co/SvaGfyDDTK https://t.co/MP9iWQK8ZB
Dr. John Cush @RheumNow( View Tweet )
Feb 28, 2022
RheumNow Podcast square

Diagnostic Delay in Axial Spondyloarthritis (2.25.2022)

Feb 25, 2022

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week, rheumatologic problems incited by respiratory infections, air pollution and how you live, now where you live.




  1. Diagnostic delay in axial spondyloarthritis? Systematic review

Read Article
CV,risk,MI,heart,cardiac

CV Risk Management in Rheumatic Disease Patients

Feb 15, 2022

The European League against Rheumatism (EULAR) has developed recommendations for cardiovascular risk (CVR) management in rheumatic disease patients based on literature review and expert consensus.



These recommendations are applicable to patients with gout, vasculitis, systemic

Read Article
Women Heroes in Rheum: - Barbara Ansell - JIA - Nanna Svartz - SSZ - Gertrude Elion - Nobel Prize for allopurinol, AZA - Tsai-Fan Yu - gout Rx - Mary Betty Stevens - lupus & vasculitis - Marian Ropes - 1st F ARA president - Fionula Brennan - TNFi & morehttps://t.co/a9tKUyWBBu https://t.co/UsHDpzJ8ma
Dr. John Cush @RheumNow( View Tweet )
Feb 09, 2022
vasculitis.Churg-Strauss_syndrome.wikipedia.jpg

ACR/EULAR 2022 Classification Criteria for EGPA

Feb 02, 2022

The 2022 ACR/EULAR revised classification criteria for eosinophilic granulomatosis with polyangiitis (EGPA) have been revised and validated for use in clinical research.



This international cohort of vasculitis and comparator cases were to develop and validate criteria based on 91

Read Article
ANCA, vasculitis, test

ACR/EULAR 2022 Classification Criteria for Microscopic Polyangiitis

Feb 02, 2022

The 2022 ACR/EULAR  classification criteria for microscopic polyangiitis (MPA) have been developed, validated and are now ready for use in clinical research.



An international cohort of patients with vasculitis or comparator diseases were recruited to first develop criteria and then

Read Article
ICYMI: NEJM clinical case -42 yoM w/ red, painful eyes, facial-nerve palsy OS, a large oral ulcer, and petechiae. +ANCA, +PR3. Skin biopsy revealed leukocytoclastic vasculitis with perivascular eosinophils. Dx eosinophilic granulomatosis with polyangiitis https://t.co/zXTQYfPa1t

Dr. John Cush @RheumNow( View Tweet )

Jan 29, 2022
NEJM clinical case - A 42 yoM w/ red, painful eyes, facial-nerve palsy OS, a large oral ulcer, and petechiae. +ANCA, +PR3. Skin biopsy revealed leukocytoclastic vasculitis with perivascular eosinophils. Dx eosinophilic granulomatosis with polyangiitis https://t.co/bPEjJr63zF

Dr. John Cush @RheumNow( View Tweet )

Jan 26, 2022
3rd Vaccine Dose May Benefit ANCA-Associated Vasculitis Patientshttps://t.co/UXUryaQ7Fz https://t.co/p40xND4lVP
Dr. John Cush @RheumNow( View Tweet )
Jan 21, 2022
Yesterdays RheumNow Live Vote survey of 170 Rheumatologists, showed that 74-80% of Rheums are reporting shortages of IV tocilizumab (Actemra) -- TCZ listed by FDA site as a drug in shortage largely due to demand, Genentech says there is supply https://t.co/YAvR4vbVHV
Dr. John Cush @RheumNow( View Tweet )
Jan 21, 2022
syringe,needle,vaccine

3rd Vaccine Dose May Benefit ANCA-Associated Vasculitis Patients

Jan 20, 2022

ARD has publish a prospective, multicenter, observational study of vaccination outcomes in antineutrophil cytoplasmic antibodies associated vasculitis (AAV) patients, showing that AAV patients may not be adequately protected after standard two-dose COVID-19 vaccination, but that a

Read Article
COVID Test Antibody

Weak Vaccine Responses in ANCA-Associated Vasculitis Patients

MedPage Today
Jan 18, 2022

Patients with ANCA-associated vasculitis (AAV) did not mount durable antibody responses to the SARS-CoV-2 Delta variant after the standard two-dose regimen of the Pfizer-BioNTech vaccine -- and for those taking rituximab (Rituxan) as maintenance therapy, even a third dose wasn't much help.

Read Article
2021,year

2021 Rheumatology Year in Review

Jan 08, 2022

Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

Read Article
covid coronavirus virus

New Onset Rheumatic Disorders with COVID-19 Infection

Jan 05, 2022

The journal Cells has published a review of new rheumatic disorders following COVID-19 infection. Rheumatologists have infrequently noted such events and wondered what is the true incidence or range of possible manifestations.



Infection can be an infrequent trigger to immune 

Read Article
Best of 2021: Cutaneous manifestations of ANCA-assoc vasculitis studied in 1184 GPA, MPA, EGPA pts and found to assoc w/ more severe disease. Common were petechiae/purpura (15%); allergic Sxs such as pruritus, urticaria, were more common in EGPA

Dr. John Cush @RheumNow( View Tweet )

Jan 03, 2022
×